Dopaminergic pathway reconstruction by Akt/Rheb‐induced axon regeneration
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objective: A prevailing concept in neuroscience has been that the adult mammalian central nervous system is incapable of restorative axon regeneration. Recent evidence, however, has suggested that reactivation of intrinsic cellular programs regulated by protein kinase B (Akt)/mammalian target of rapamycin (mTor) signaling may restore this ability. Methods: To assess this possibility in the brain, we have examined the ability of adenoassociated virus (AAV)‐mediated transduction of dopaminergic neurons of the substantia nigra (SN) with constitutively active forms of the kinase Akt and the GTPase Ras homolog enriched in brain (Rheb) to induce regrowth of axons after they have been destroyed by neurotoxin lesion. Results: Both constitutively active myristoylated Akt and hRheb(S16H) induce regrowth of axons from dopaminergic neurons to their target, the striatum. Histological analysis demonstrates that these new axons achieve morphologically accurate reinnervation. In addition, functional reintegration into target circuitry is achieved, as indicated by partial behavioral recovery. Interpretation: We conclude that regrowth of axons within the adult nigrostriatal projection, a system that is prominently affected in Parkinson's disease, can be achieved by activation of Akt/mTor signaling in surviving endogenous mesencephalic dopaminergic neurons by viral vector transduction. ANN NEUROL 2011
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
Promoting Axon Regeneration in the Adult CNS by Modulation of the PTEN/mTOR Pathway
Park, K. K., Liu, K., Hu, Y., Smith, P. D., Wang, C., Cai, B., Xu, B., Connolly, L., Kramvis, I., Sahin, M., et al. (2008) · Science · doi:10.1126/science.1161566 · Cited by 1,686
Self-citationThe TSC1–TSC2 complex: a molecular switchboard controlling cell growth
Huang, J., & Manning, B. D. (2008) · Biochemical Journal · doi:10.1042/bj20080281 · Cited by 1,237 · cited 1×
“The GTPase Rheb is a principal activator of mTor.(32,33) We herein demonstrate that transduction of SN neurons with hRheb(S16H) activates mTor, indicated by increased p4EBP1.”
BackgroundClinical progression in Parkinson disease and the neurobiology of axons
Cheng, H., Ulane, C. M., & Burke, R. E. (2010) · Annals of Neurology · doi:10.1002/ana.21995 · Cited by 1,012 · cited 1×
“However, even if these findings are confined to the dopaminergic nigrostriatal projection, they nevertheless have implications for the treatment of Parkinson’s disease, which has been proposed to initially involve axons, and in which even partial reinnervation may be sufficient to restore normal motor function.(34) Bo…”
BackgroundSelf-citation
Cited by
Axon degeneration in Parkinson's disease
Burke, R. E., & O'Malley, K. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.01.011 · Cited by 493
Self-citationmTOR in Brain Physiology and Pathologies
Bockaert, J., & Marin, P. (2015) · Physiological Reviews · doi:10.1152/physrev.00038.2014 · Cited by 356
Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson’s Disease
Subramaniam, S. R., & Federoff, H. J. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00176 · Cited by 347
Retrograde Axonal Degeneration in Parkinson Disease
Tagliaferro, P., & Burke, R. E. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-150769 · Cited by 272
“Efforts to induce new axon growth in mature neurons by rejuvenating the pathways that are responsible for axon growth during development have had substantial success [84, 89].”
BackgroundSelf-citationBalancing mTOR Signaling and Autophagy in the Treatment of Parkinson’s Disease
Zhu, Z., Yang, C., Iyaswamy, A., Krishnamoorthi, S., Sreenivasmurthy, S. G., Liu, J., Wang, Z., Tong, B. C.-K., Song, J., Lu, J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030728 · Cited by 263
Athauda, D., Gulyani, S., Karnati, H. K., Li, Y., Tweedie, D., Mustapic, M., Chawla, S., Chowdhury, K., Skene, S. S., Greig, N. H., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4304 · Cited by 258
Tonges, L., Frank, T., Tatenhorst, L., Saal, K. A., Koch, J. C., Szego, E. M., Bahr, M., Weishaupt, J. H., & Lingor, P. (2012) · Brain · doi:10.1093/brain/aws254 · Cited by 176
“Scale bar = 1 mm. rapamycin (Rheb/mTor) pathway, which can foster axon growth and halt nigral cell death following striatal 6-hydroxydopamine lesion upon activation by adeno-associated virus transduction of substania nigra neurons with constitutively active Rheb (Kim et al., 2011b, 2012).”
BackgroundMethodBeneficial Effects of Flavonoids Against Parkinson's Disease
Jung, U. J., & Kim, S. R. (2018) · Journal of Medicinal Food · doi:10.1089/jmf.2017.4078 · Cited by 150
“86,87 These results suggest that induction of mTORC1 activation may be necessary for axonal regeneration in the lesioned adult brain in vivo , and it may be useful as a therapeutic strategy to treat patients with neurodegenerative diseases such as PD.”
InfluentialSelf-citationIncretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., & Edison, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01792-4 · Cited by 136
Kim, S. R., Kareva, T., Yarygina, O., Kholodilov, N., & Burke, R. E. (2012) · Molecular Therapy · doi:10.1038/mt.2011.213 · Cited by 107
Self-citationDello Russo, C., Lisi, L., Feinstein, D. L., & Navarra, P. (2013) · Glia · doi:10.1002/glia.22433 · Cited by 96
“The kinase was found activated during axonal regeneration after damage, as it occurs in the striatum (Kim et al., 2011), in the cerebellar granule neurons (Okada et al., 2011), after optic nerve injury (Park et al., 2008), and in peripheral nerves (Abe et al., 2010).”
BackgroundNam, J. H., Leem, E., Jeon, M.-T., Jeong, K. H., Park, J.-W., Jung, U. J., Kholodilov, N., Burke, R. E., Jin, B. K., & Kim, S. R. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8729-2 · Cited by 76
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.02.010 · Cited by 58
The scheduling of adolescence with Netrin-1 and UNC5C
Hoops, D., Kyne, R., Salameh, S., MacGowan, D., Avramescu, R. G., Ewing, E., He, A. T., Orsini, T., Durand, A., Popescu, C., et al. (2024) · eLife · doi:10.7554/elife.88261 · Cited by 8
Metadata
- Authors
- Kim, S. R., Chen, X., Oo, T. F., Kareva, T., Yarygina, O., Wang, C., During, M., Kholodilov, N., & Burke, R. E.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2011-03-17
- Volume
- 70
- Issue
- 1
- Pages
- 110-120
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2160463463
- Cited by
- 143
- References
- 5
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.